SARS-CoV-2 - Methylprednisolone - Therapeutic Candidates

SARS-CoV-2 - Methylprednisolone - Therapeutic Candidates


Methylprednisolone is the active substance of Medrol and Solu-Medrol. This molecule is a corticoid of the glucocorticoid family (such as prednisolone or cortisol). Methylprednisolone belongs to the category of steroidal anti-inflammatory drugs and is used in various anti-inflammatory treatments such as allergy treatment. 
It appears that methylprednisolone may reduce mortality in patients with very severe forms of Covid-19. These patients had developed acute respiratory distress syndrome (ARDS) which is a mechanism causing morbidity and mortality in Covid-19 patients. However, these results are controversial because generally speaking, in severe viral pneumonia, corticosteroid treatments are considered contraindicated because of the suppression of the innate immune system they cause. Methylprednisolone could therefore be a potential candidate for treatment of Covid-9 caused by CoV-2-SARS but only for very severe forms.

Cat#
Description
Size
Price Excl. VAT
HY-B0260-100mg
 100mg 
HY-B0260-500mg
 500mg 
HY-B1900-S
 0,5-1mg 
HY-B0260-S
 0,5-1mg 
HY-B0260-1mL
 10mM/1mL 
HY-B1900-1mL
 10mM/1mL 
HY-B1900-10mg
 10mg 
HY-B1900-50mg
 50mg 
HY-B1900-100mg
 100mg 
HY-B1900-200mg
 200mg 
S1171-100mg
 100mg 
S1171-200mg
 200mg 
M326935-0.5mg
 0.5mg 
M326935-2.5mg
 2.5mg 
A4233-1ml
 10 mM (in 1mL DMSO) 
OORB00156
 500 ul 
A4233-1000mg
 1 g 
A10582-100
 100mg 
A10582-250
 250mg 
A10582-500
 500mg 
A10582-1000
 1000mg 
412180-25mg
 25mg 
412180-50mg
 50mg 
Number of results per page : 10 50 250